Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GRK2 | P25098 | 1/20 | 0.30 |
| ▸ | CASP6 | P55212 | 1/20 | 0.30 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29280264 | 0.80 | FBP1 (0.32) | FBP1 | |
| SCHEMBL29712319 | 0.76 | TDP1 (0.35) | — | |
| SCHEMBL11201007 | 0.71 | FBP1 (0.33) | FBP1 | |
| SCHEMBL28715877 | 0.69 | — | — | |
| SCHEMBL6343793 | 0.69 | TBXAS1 (0.41) | — | |
| Ammonia Solution, Strong SCHEMBL4273820 | 0.67 | — | — | |
| SCHEMBL17178422 | 0.67 | — | — | |
| SCHEMBL21546027 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL27938729 | 0.67 | — | — | |
| SCHEMBL28125024 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024086562-A2 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-04-25 | — | — | WO | claimed |
| CN-109312247-A | Mercaptopyrrole Derivatives as Lubricant Additives | 路博润公司 | 2019-02-05 | — | — | CN | claimed |
| US-10167501-B2 | Methods and apparatus for quantification of nucleic acid amplification by monitoring impedances | AUCKLAND UNISERVICES LIMITED (NZ) | 2019-01-01 | — | — | US | claimed |
| WO-2018140478-A1 | VIRAL RESISTANT CELLS AND CULTURE SYSTEMS | SIGMA-ALDRICH CO. LLC (US) | 2018-08-02 | — | — | WO | claimed |
| CN-108200770-A | Pyrrole derivatives as lubricant additives | 路博润公司 | 2018-06-22 | — | — | CN | claimed |
| CN-108138070-A | Pyrrole derivatives as lubricant additives | 路博润公司 | 2018-06-08 | — | — | CN | claimed |
| US-20160046977-A1 | Methods and Apparatus for Amplifying Nucleic Acids | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-02-18 | — | — | US | claimed |
| US-20140086977-A1 | TIGHT JUNCTIONS MODULATORS | THE UNIVERSITY OF MANCHESTER (GB) | 2014-03-27 | — | — | US | claimed |
| EP-2691090-A2 | TIGHT JUNCTIONS MODULATORS | The University Of Manchester (GB) | 2014-02-05 | — | — | EP | claimed |
| WO-2012131341-A2 | TIGHT JUNCTIONS MODULATORS | THE UNIVERSITY OF MANCHESTER (GB) | 2012-10-04 | — | — | WO | claimed |
| EP-0802782-B1 | PROPHYLACTIC AND THERAPEUTIC TREATMENT OF SKIN SENSITIZATION AND IRRITATION | BRISTOL MYERS SQUIBB CO (US) | 2003-02-05 | — | — | EP | claimed |
| US-5995869-A | Reduction of skin sensitization in electrotransport drug delivery | ALZA CORPORATION (US) | 1999-11-30 | — | — | US | claimed |
| US-5912010-A | ADMINISTERING LOOP DIURETIC ALONE OR WITH MAST CELL DEGRANULATOR OR GLUCOCORTICOSTEROID | E.R. SQUIBB & SONS, INC. (US) | 1999-06-15 | — | — | US | claimed |
| US-5843979-A | Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-12-01 | — | — | US | claimed |
| EP-0802782-A4 | PROPHYLACTIC AND THERAPEUTIC TREATMENT OF SKIN SENSITIZATION AND IRRITATION | BRISTOL MYERS SQUIBB CO (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1997047355-A1 | REDUCTION OF SKIN SENSITIZATION IN ELECTROTRANSPORT DRUG DELIVERY | ALZA CORPORATION (US) | 1997-12-18 | — | — | WO | claimed |
| US-5686100-A | Prophylactic and therapeutic treatment of skin sensitization and irritation | E.R. SQUIBB & SONS, INC. (US) | 1997-11-11 | — | — | US | claimed |
| EP-0802782-A1 | PROPHYLACTIC AND THERAPEUTIC TREATMENT OF SKIN SENSITIZATION AND IRRITATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-10-29 | — | — | EP | claimed |
| WO-1996015771-A1 | PROPHYLACTIC AND THERAPEUTIC TREATMENT OF SKIN SENSITIZATION AND IRRITATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-05-30 | — | — | WO | claimed |
| EP-0612525-A1 | Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-08-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140086977-A1 | TIGHT JUNCTIONS MODULATORS | DSG1, KRT18, STOM | FBP1 2748/4885NSD2 4447/4885POLB 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.